INT106261

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 2002
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 16
Total Number 32
Disease Relevance 15.02
Pain Relevance 1.19

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (DPYD) small molecule metabolic process (DPYD) oxidoreductase activity (DPYD)
cytoplasm (DPYD)
Anatomy Link Frequency
foot 2
blood 1
plasma 1
DPYD (Homo sapiens)
Pain Link Frequency Relevance Heat
gABA 2 99.28 Very High Very High Very High
tolerance 3 98.14 Very High Very High Very High
anticonvulsant 2 97.52 Very High Very High Very High
fluoxetine 12 95.52 Very High Very High Very High
Antihistamine 8 90.16 High High
palliative 20 86.08 High High
alcohol 10 82.96 Quite High
Pain 5 78.56 Quite High
antiepileptic Drug 4 58.52 Quite High
carbamazepine 8 57.12 Quite High
Disease Link Frequency Relevance Heat
Dihydropyrimidine Dehydrogenase Deficiency 4 100.00 Very High Very High Very High
Cancer 365 99.70 Very High Very High Very High
Toxicity 559 99.60 Very High Very High Very High
Syndrome 66 99.00 Very High Very High Very High
Neurological Disease 17 99.00 Very High Very High Very High
Death 8 98.80 Very High Very High Very High
Anxiety Disorder 2 96.76 Very High Very High Very High
Hypercalcemia 8 93.28 High High
Exanthema 14 92.36 High High
Rectal Cancer 10 90.24 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The high prevalence of c.1905 + 1G>A mutations in cancer patients with a reduced DPD activity from the Netherlands is in line with a previous study in tumour patients with severe 5FU toxicity (van Kuilenburg et al. 2002a).
Negative_regulation (reduced) of DPD associated with toxicity and cancer
1) Confidence 0.59 Published 2010 Journal Hum Genet Section Body Doc Link PMC2955237 Disease Relevance 0.88 Pain Relevance 0.06
We present a case with dihydropyrimidine dehydrogenase (DPD) deficiency that manifested a variant of hand-foot syndrome (HFS).
Negative_regulation (deficiency) of dihydropyrimidine dehydrogenase in foot associated with syndrome
2) Confidence 0.58 Published 2006 Journal Clin Colorectal Cancer Section Abstract Doc Link 17026792 Disease Relevance 0.82 Pain Relevance 0.08
We present a case with dihydropyrimidine dehydrogenase (DPD) deficiency that manifested a variant of hand-foot syndrome (HFS).
Negative_regulation (deficiency) of DPD in foot associated with syndrome
3) Confidence 0.58 Published 2006 Journal Clin Colorectal Cancer Section Abstract Doc Link 17026792 Disease Relevance 0.82 Pain Relevance 0.08
The reduction of 5alpha-dihydroprogesterone (5alpha-DHP), the last step in allopregnanolone biosynthesis, is catalyzed by 3alpha-hydroxysteroid dehydrogenases (3alpha-HSDs).
Negative_regulation (reduction) of DHP
4) Confidence 0.57 Published 2002 Journal Biochemistry Section Abstract Doc Link 12416991 Disease Relevance 0.10 Pain Relevance 0.15
The fact that a genomic deletion affecting DPYD was observed in only 1 out of 92 patients with reduced DPD activity and/or severe 5FU toxicity indicates that rearrangements in DPYD are not a major genetic cause underlying a partial DPD deficiency.
Negative_regulation (reduced) of DPD associated with toxicity
5) Confidence 0.51 Published 2010 Journal Hum Genet Section Body Doc Link PMC2955237 Disease Relevance 0.53 Pain Relevance 0
In the present study, unambiguous evidence for such a large genomic deletion within DPYD was obtained in a patient with reduced DPD activity and severe 5FU toxicity.
Negative_regulation (reduced) of DPD associated with toxicity
6) Confidence 0.51 Published 2010 Journal Hum Genet Section Body Doc Link PMC2955237 Disease Relevance 0.81 Pain Relevance 0
DPD deficiency is known to cause a potentially lethal toxicity following administration of 5FU.
Negative_regulation (deficiency) of DPD associated with toxicity
7) Confidence 0.43 Published 2010 Journal Hum Genet Section Abstract Doc Link PMC2955237 Disease Relevance 0.28 Pain Relevance 0
However, in a significant number of patients with a reduced DPD activity, no mutations could be identified in the coding part of DPYD (Collie-Duguid et al. 2000; Mattison et al. 2004; van Kuilenburg et al. 2000).
Negative_regulation (reduced) of DPD
8) Confidence 0.43 Published 2010 Journal Hum Genet Section Body Doc Link PMC2955237 Disease Relevance 0.32 Pain Relevance 0
MLPA analysis showed the presence of the c.1905 + 1G>A (IVS14 + 1G>A) mutation in 28% (18/64) and 9% (1/11) of cancer patients with a reduced DPD activity from the Netherlands and France, respectively.
Negative_regulation (reduced) of DPD associated with cancer
9) Confidence 0.43 Published 2010 Journal Hum Genet Section Body Doc Link PMC2955237 Disease Relevance 0.27 Pain Relevance 0
Dihydropyrimidine dehydrogenase deficiency, if undiagnosed, can lead to death.
Negative_regulation (deficiency) of Dihydropyrimidine dehydrogenase associated with dihydropyrimidine dehydrogenase deficiency and death
10) Confidence 0.43 Published 2006 Journal Clin Colorectal Cancer Section Abstract Doc Link 17026792 Disease Relevance 1.26 Pain Relevance 0.07
We report here determination of the kinetic mechanism for 5alpha-DHP reduction catalyzed by human 3alpha-HSD type III by using steady-state kinetics studies and assessment of the ability of fluoxetine and various other small molecules to activate 3alpha-HSD type III catalyzed allopregnanolone formation.
Negative_regulation (reduction) of DHP associated with fluoxetine
11) Confidence 0.42 Published 2002 Journal Biochemistry Section Abstract Doc Link 12416991 Disease Relevance 0.08 Pain Relevance 0.17
Because fluorouracil is minimally excreted by the renal route (about 10% of the dose) and is almost entirely metabolized by dihydropyrimidine dehydrogenase (DPD), it is suggested that plasma factors that accumulate during the interdialytic period and are removed by dialysis may inhibit DPD activity and, consequently, fluorouracil metabolic clearance.
Negative_regulation (inhibit) of DPD in plasma
12) Confidence 0.38 Published 2005 Journal Ther Drug Monit Section Abstract Doc Link 16306860 Disease Relevance 0.20 Pain Relevance 0.06
Quantitative PCR showed that the ratio of the mutant DPD mRNA lacking exon 22 and wild-type DPD mRNA was 25 ± 3%.
Negative_regulation (lacking) of DPD mRNA
13) Confidence 0.38 Published 2010 Journal Hum Genet Section Body Doc Link PMC2955237 Disease Relevance 0 Pain Relevance 0
The study cohort consisted of 64 Dutch patients who had been referred for diagnostic purposes between 2007 and 2009 and proved to have a reduced DPD activity in peripheral blood mononuclear cells (Milano et al. 1999; van Kuilenburg et al. 2002b), ranging from 0.7–5.9 nmol/mg/h (local controls 9.6 ± 2.6 nmol/mg/h).
Negative_regulation (reduced) of DPD in blood
14) Confidence 0.38 Published 2010 Journal Hum Genet Section Body Doc Link PMC2955237 Disease Relevance 0.66 Pain Relevance 0
Ninety-two cancer patients with reduced DPD activity and/or grade III/IV toxicity were examined for DPYD rearrangements.
Negative_regulation (reduced) of DPD associated with toxicity and cancer
15) Confidence 0.38 Published 2010 Journal Hum Genet Section Body Doc Link PMC2955237 Disease Relevance 0.54 Pain Relevance 0
In this respect, it has been shown that a DPD deficiency is an important pharmacogenetic syndrome and the identification of predictive genetic markers of toxicity has become a challenging topic in the field of oncology (Amstutz et al. 2009; Gross et al. 2008; Morel et al. 2006).
Negative_regulation (deficiency) of DPD associated with toxicity and syndrome
16) Confidence 0.38 Published 2010 Journal Hum Genet Section Body Doc Link PMC2955237 Disease Relevance 0.58 Pain Relevance 0.09
Quantitative PCR showed that the ratio of the mutant DPD mRNA lacking exon 22 and wild-type DPD mRNA was 25 ± 3%.
Negative_regulation (lacking) of DPD mRNA
17) Confidence 0.38 Published 2010 Journal Hum Genet Section Body Doc Link PMC2955237 Disease Relevance 0 Pain Relevance 0
Four additional Dutch subjects of whom exonic sequence data were available, including two patients with severe 5FU toxicity, a son of a patient with lethal toxicity and a healthy volunteer who was coincidently found to have a DPD deficiency during another study were further investigated for intronic mutations and alternative splicing.
Negative_regulation (deficiency) of DPD associated with toxicity
18) Confidence 0.38 Published 2010 Journal Hum Genet Section Body Doc Link PMC2955237 Disease Relevance 1.05 Pain Relevance 0
Here, we report novel genetic mechanisms underlying DPD deficiency in patients presenting with grade III/IV 5FU-associated toxicity.
Negative_regulation (deficiency) of DPD associated with toxicity
19) Confidence 0.38 Published 2010 Journal Hum Genet Section Abstract Doc Link PMC2955237 Disease Relevance 0.28 Pain Relevance 0
For that reason, various strategies have been proposed to screen for patients with a DPD deficiency, including genotyping (Amstutz et al. 2009; Kleibl et al. 2009).
Negative_regulation (deficiency) of DPD
20) Confidence 0.38 Published 2010 Journal Hum Genet Section Body Doc Link PMC2955237 Disease Relevance 0.33 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox